These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 21585174)
1. Neuroprotective effects of sodium hydrosulfide against β-amyloid-induced neurotoxicity. Li XH; Deng YY; Li F; Shi JS; Gong QH Int J Mol Med; 2016 Oct; 38(4):1152-60. PubMed ID: 27511125 [TBL] [Abstract][Full Text] [Related]
2. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Sperling H; Debruyne F; Boermans A; Beneke M; Ulbrich E; Ewald S J Sex Med; 2010 Apr; 7(4 Pt 1):1497-507. PubMed ID: 20233275 [TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations. Lombardo R; Tema G; De Nunzio C Curr Drug Targets; 2021; 22(1):31-37. PubMed ID: 32981502 [TBL] [Abstract][Full Text] [Related]
4. Time to onset of action of vardenafil: a retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations. Debruyne FM; Gittelman M; Sperling H; Börner M; Beneke M J Sex Med; 2011 Oct; 8(10):2912-23. PubMed ID: 21883954 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials. Heinig R; Weimann B; Dietrich H; Böttcher MF Clin Drug Investig; 2011; 31(1):27-41. PubMed ID: 20925442 [TBL] [Abstract][Full Text] [Related]
6. The management of erectile dysfunction: innovations and future perspectives. Leonardi R; Alemanni M Arch Ital Urol Androl; 2011 Mar; 83(1):60-2. PubMed ID: 21585174 [TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation. Scaglione F; Donde S; Hassan TA; Jannini EA Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291 [TBL] [Abstract][Full Text] [Related]
9. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Wright PJ Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568 [TBL] [Abstract][Full Text] [Related]
10. [Modernity in the treatment of erectile dysfunction: Levitra (vardenafil) in the form of oral dispersible tablet]. Gamidov SI; Iremashvili VV; Popova AIu Urologiia; 2013; (3):102-4, 106. PubMed ID: 23987060 [TBL] [Abstract][Full Text] [Related]
11. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature. Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626 [TBL] [Abstract][Full Text] [Related]